INEOS Quattro: conference call comments|NIH: improvement in certain indicators in H2, but still little visibility on M&A|Ardagh Group surprises with strong increase in glass EBITDA in Q4|Clariane : Satisfactory 2025 results thanks to strong recovery in H2 25 and B2/B+ ratings assigned by Moody’s and S&P|
INEOS Quattro: conference call comments|NIH : amélioration de certains indicateurs au S2 mais toujours peu de visibilité sur le M&A|Ardagh Group surprend avec une forte hausse de l’EBITDA verre au T4|Clariane : Résultats 2025 satisfaisants grâce à un bon rattrapage au 2nd semestre et ratings B2/B+ attribués par Moody’s et S&P|
HEADLINES: • AmRest: 4Q25 miss, due mainly to allegations about food safety in Czechia NEGATIVE • Kruk: 4Q25 results – bit of a mixed bag • Text: 3Q25-26 (calendar 4Q25) results – EBITDA down 25% yoy, 3% above the consensus NEUTRAL • Enea: impairments and higher provisions to reduce 2025 net income by PLN 1.37bn and EBITDA by PLN 162m NEUTRAL • CTP: 4Q25 results and conference call • Richter: 4Q25 beat, on gross margin and tight opex control POSITIVE • Duna House: 4Q25 in line, guidance implies ...
NEWS SUMMARY: ACCIONA, ACCIONA ENERGÍA, ACERINOX, AMADEUS, CELLNEX, COLONIAL, ELECTRICITY SECTOR, FCC, GLOBAL DOMINION, GRIFOLS, IAG, MERLIN, OHLA, REDEIA, SACYR, SOLARIA, VISCOFAN. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 4Q’25 results to be released over the coming days in Spain. Doubts continue to plague Nasdaq, but software rallies after harsh punishment European s...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.